Components:
Method of action:
Treatment option:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 23.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Acylpyrin is indicated to:
- Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina
- Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack
Limitation of Use
Use immediate-release aspirin, not Acylpyrin in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention).
The recommended dose of Acylpyrin is one capsule (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day.
Swallow Acylpyrin capsules whole. Do not cut, crush or chew capsules.
Do not take Acylpyrin 2 hours before or 1 hour after consuming alcohol.
Acylpyrin is contraindicated:
- In patients with a hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).
- In patients with the syndrome of asthma, rhinitis, and nasal polyps. Acylpyrin may cause severe urticaria, angioedema, or bronchospasm.
WARNINGS
Included as part of the PRECAUTIONS section.
PRECAUTIONS
Risk Of Bleeding
Acylpyrin increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs).
Peptic Ulcer Disease
Acylpyrin may cause gastric ulceration and bleeding. Avoid Acylpyrin in patients with active peptic ulcer disease.
Fetal Toxicity
Acylpyrin can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because NSAIDs may cause premature closure of the fetal ductus arteriosus, avoid Acylpyrin in the third trimester of pregnancy.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment Of Fertility
No carcinogenesis, mutagenesis or impairment of fertility studies were conducted with Acylpyrin. Aspirin is not considered to be genotoxic or carcinogenic. Studies with oral aspirin in pregnant rats demonstrated the occurrence of fetal malformations at oral doses at or above 250 mg/kg [Human equivalent dose (HED) 40 mg/kg].
Use In Specific Populations
Pregnancy
Avoid use during the third trimester of pregnancy because NSAIDs such as Acylpyrin may cause premature closure of the fetal ductus arteriosus. Salicylate products have also been associated with alterations in maternal and neonatal hemostasis mechanisms, decreased birth weight, and with perinatal mortality.
Labor And Delivery
Avoid Acylpyrin 1 week prior to and during labor and delivery because it can result in excessive blood loss at delivery. Prolonged gestation and prolonged labor due to prostaglandin inhibition have been reported.
Nursing Mothers
Because of the potential for serious adverse reactions in nursing infants from Acylpyrin, choose either to discontinue Acylpyrin or discontinue nursing.
Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
Geriatric Use
In a large collaborative overview of aspirin for vascular event prevention, including over 14000 patients over 65 years of age, no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Hepatic Impairment
Avoid Acylpyrin in patients with severe hepatic insufficiency.
Renal Impairment
Avoid Acylpyrin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute).
Clinical Trials Experience
The following is a list of adverse reactions that have been reported in the literature for products containing low dose aspirin.
Central Nervous System: Agitation, cerebral edema, coma, confusion, dizziness, headache, lethargy, seizures.
Fluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis.
Gastrointestinal: Dyspepsia, hepatic enzyme elevation, hepatitis, Reye's Syndrome
Renal: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure.
Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 mcg/mL. Plasma concentrations of aspirin above 300 mcg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 mcg/mL. A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 g. For real or suspected overdose, contact a Poison Control Center immediately.
Signs and Symptoms
In acute overdose, severe acid-base and electrolyte disturbances may occur and are complicated by hyperthermia and dehydration. Respiratory alkalosis occurs early while hyperventilation is present, but is quickly followed by metabolic acidosis.
Treatment
Treatment consists primarily of supporting vital functions, increasing salicylate elimination, and correcting the acid-base disturbance. Gastric emptying or lavage is recommended as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage or emesis, administer activated charcoal, as a slurry, if less than 3 hours have passed since ingestion.
Severity of aspirin intoxication is determined by measuring the blood salicylate level. Monitor acid-base status with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance.
In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Replace fluid intravenously and correct acidosis. Monitor plasma electrolytes and pH to promote alkaline diuresis of salicylate if renal function is normal. Glucose may be required to control hypoglycemia.
Hemodialysis and peritoneal dialysis can reduce the body aspirin content. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required. Exchange transfusion may be indicated in infants and young children.
The dose-response relationship for Acylpyrin and immediate release (IR) aspirin towards COX-1 inhibition was characterized by examining the inhibition of serum TXB2 and urine 11dehydro-TXB2 at 24 h following a single dose. Doses over the range of 20 mg to 325 mg for Acylpyrin and 5 mg to 81 mg for IR aspirin respectively were studied. Half-maximal inhibition of serum TXB2 and urine 11-dehydro-TXB2 occurred with doses of Acylpyrin (ID50) about 2-fold the dose of immediate release (IR) aspirin. Based on this relationship, the pharmacodynamic effect of Acylpyrin 162.5 mg is similar to that attained with IR aspirin 81 mg. The mean inhibition of serum TXB2 following Acylpyrin (82%) is lower when compared to IR aspirin 81 mg (93%) following the first dose. However, upon repeat administration, near maximal inhibition of serum TXB2 is achieved, similar to what is achieved following repeated daily doses of IR aspirin.
Following oral administration, Acylpyrin exhibits extended release of aspirin from the encapsulated microparticles, thereby prolonging the absorption of aspirin across the GI tract compared to IR aspirin (Figure 1). Once absorbed, aspirin is metabolized, distributed, and excreted in a manner similar to that of aspirin absorbed from IR dosage forms.
Figure 1: Mean acetylsalicylic acid concentration-time profile following single dose administration of 162.5 mg Acylpyrin or 81 mg immediate release ASA
Absorption
Following administration of Acylpyrin, the time to reach peak plasma concentration of aspirin is slightly longer compared to following IR aspirin dosage form. Median Tmax for Acylpyrin is about 2 h when compared to 1 h following IR aspirin (see Figure 1). The mean Cmax for Acylpyrin is approximately 35% of that following IR aspirin 81 mg. The area under the plasma concentration-time curve for aspirin following administration of Acylpyrin is approximately 70% of that following IR aspirin. The rate of Acylpyrin absorption is dependent on food, alcohol, and gastric pH.
Distribution
The volume of distribution of usual doses of aspirin in normal subjects averages approximately 170 mL/kg of body weight.
Metabolism
Aspirin is rapidly hydrolyzed in the plasma to salicylic acid such that plasma levels of aspirin following Acylpyrin administration are essentially undetectable 4-8 hours after dosing. In contrast to immediate release aspirin, measurable levels of salicyclic acid at 24 hours following a single dose of Acylpyrin were observed. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
Elimination
The mean plasma half-life of aspirin may range from 20 to 60 min. Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicylic acid, and 10% phenolic and 5% acyl glucuronides of salicylic acid.
- Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data
- The hospital management practices in Chinese county hospitals and its association with quality of care, efficiency and finance
- Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance
- Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
- COVID-19 pericarditis mimicking an acute myocardial infarction: a case report and review of literature
- Characteristics of inflammatory phenotypes among patients with asthma: relationships of blood count parameters with sputum cellular phenotypes
- Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
- The role of sex and inflammation in cardiovascular outcomes and mortality in COVID-19
- Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
- A Case Series of Life-Threatening Hemorrhagic Events in Patients with COVID-19
- Critical evaluation of stents in coronary angioplasty: a systematic review
- Accessing routinely collected health data to improve clinical trials: recent experience of access
- Focal onset non-motor seizure following COVID-19 vaccination: A mere coincidence?
- Efficacy and safety of Naoxintong capsule for treating chronic stable angina: study protocol for a randomized controlled trial
- The effects of topical erythropoietin on non-surgical treatment of periodontitis: a preliminary study
- A breastfeeding woman with spontaneous coronary artery dissection and possible takotsubo syndrome
- Type 1 Kounis syndrome induced by inactivated SARS-CoV-2 vaccine
- Clinical implication of homocysteine in premature acute coronary syndrome female patients
- Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study
- Lacosamide induced Brugada I morphology in the setting of septicemia
However, we will provide data for each active ingredient